Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Opportunities and Obstacles to the Development of Nanopharmaceuticals for Human Use Publisher Pubmed



Nassiri Koopaei N1 ; Abdollahi M2, 3, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmaceutics, School of Pharmacy, University of Florida, Orlando, United States
  2. 2. Department of Toxicology and Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Toxicology Interest Group, Universal Scientific Education and Research Network, Tehran University of Medical Sciences, Tehran, Iran

Source: DARU# Journal of Pharmaceutical Sciences Published:2016


Abstract

Pharmaceutical nanotechnology has generated breakthrough developments in improving health care and human life from its emergence. The biomaterials employed mainly aim at improving drug delivery systems, imaging and diagnostic technologies while the nanoscale materials are in widespread use in other industries such as electronics and optics. Such advancement may revolutionize the drug development and therapy with new and more efficient treatments. Although, nanotechnology assists humankind in improving its well being, it has certain limitations that entail thorough investigation by the regulatory and scientific authorities. To address concerns regarding the safety and toxicity profile of the nanopharmaceuticals, we have reviewed the challenges and solutions of nanopharmaceuticals use in human health and the related health risks. In this regard, regulatory and scientific bodies such as countries’ Food and Drug Administration (FDA), Organization for Economic Co-operation and Development (OECD), European Medicine Agency (EMA), Environmental Protection Agency (EPA), National Institute for Occupational Safety and Health (NIOSH), and World Health Organization (WHO) can participate in developing and reinforcing safety measures and regulatory frameworks to insure the public health. The regulatory authorities may enforce the nanopharmaceutical industries to conduct comprehensive toxicity tests and monitor the adverse drug reaction reports in close collaboration with the scientific community to act accordingly and inform the public as the implementation of the strategy. Graphical abstract: Nanopharmaceuticals have tremendous potential for human use as therapeutic or diagnostic agents. But their toxicity profile should be well addressed and the respective regulatory framework developed and reinforced by the authorities. © 2016 The Author(s).
Related Docs
1. Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities, Nanomedicine (2019)
2. Growing Knowledge of Using Embryonic Stem Cells As a Novel Tool in Developmental Risk Assessment of Environmental Toxicants, Life Sciences (2016)
3. Toxicity of Nanoparticles and an Overview of Current Experimental Models, Iranian Biomedical Journal (2016)
4. Advances in the Anticancer Value of the Ursolic Acid Through Nanodelivery, Current Medicinal Chemistry (2018)
5. Protein Corona Variation in Nanoparticles Revisited: A Dynamic Grouping Strategy, Colloids and Surfaces B: Biointerfaces (2019)
6. Polyphenol Nanoformulations for Cancer Therapy: Experimental Evidence and Clinical Perspective, International Journal of Nanomedicine (2017)
7. From in Vitro Experiments to in Vivo and Clinical Studies; Pros and Cons, Current Drug Discovery Technologies (2015)
8. A Systematic Review of Nano Formulation of Natural Products for the Treatment of Inflammatory Bowel Disease: Drug Delivery and Pharmacological Targets, DARU# Journal of Pharmaceutical Sciences (2018)
Experts (# of related papers)
View all Related Experts
Mohammad Abdollahi (6)
Roja Rahimi (2)